Cargando…
Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1
BACKGROUND: Corticosteroid-free clinical remission is important in ulcerative colitis. OBJECTIVE: This GEMINI 1 post hoc analysis evaluated vedolizumab efficacy in achieving sustained corticosteroid-free clinical remission in moderately to severely active ulcerative colitis. MATERIALS AND METHODS: G...
Autores principales: | Loftus, Edward V, Sands, Bruce E, Colombel, Jean-Frédéric, Dotan, Iris, Khalid, Javaria Mona, Tudor, David, Geransar, Parnia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295209/ https://www.ncbi.nlm.nih.gov/pubmed/32606883 http://dx.doi.org/10.2147/CEG.S248597 |
Ejemplares similares
-
Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn’s Disease: A Post Hoc Analysis of GEMINI 2 and 3
por: Sands, Bruce E, et al.
Publicado: (2019) -
Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials
por: Feagan, Brian G, et al.
Publicado: (2019) -
Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis
por: Sandborn, William J, et al.
Publicado: (2019) -
Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
por: Feagan, Brian G, et al.
Publicado: (2019) -
Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1
por: Reinisch, Walter, et al.
Publicado: (2019)